PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2017; 38(02): 244-247
DOI: 10.4103/ijmpo.ijmpo_112_16
Letters to Editor

Primary Diffuse Large B-cell Lymphoma of the Breast: A Rare Case and Review of Literature

Dhruv Pankaj Mehta
Department of Medical and Paediatric Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India
,
Pushpak Chirmade
Department of Medical and Paediatric Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India
,
Asha S Anand
Department of Medical and Paediatric Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India
,
Sonia Parikh
Department of Medical and Paediatric Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India
› Institutsangaben Financial support and sponsorship Nil.
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints


Publikationsverlauf

Artikel online veröffentlicht:
06. Juli 2021

© 2017. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Yoshida S, Nakamura N, Sasaki Y, Yoshida S, Yasuda M, Sagara H, et al. Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype. Mod Pathol 2005;18:398-405.
  • 2 Lyons JA, Myles J, Pohlman B, Macklis RM, Crowe J, Crownover RL. Treatment of prognosis of primary breast lymphoma: A review of 13 cases. Am J Clin Oncol 2000;23:334-6.
  • 3 Arnold SF, Caron AJ, Peter M, Jon CA. Non-Hodgkin's lymphoma. DeVita, Hellman, and Rosenberg's cancer: Principles & practice of oncology: 10th ed. Wolters Kluwer Health Adis (ESP); 2015. p. 1552-83.
  • 4 Yhim HY, Kang HJ, Choi YH, Kim SJ, Kim WS, Chae YS, et al. Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) study. BMC Cancer 2010;10:321.
  • 5 Ganjoo K, Advani R, Mariappan MR, McMillan A, Horning S: Non-Hodgkin lymphoma of the breast. Cancer 2007;110:25-30.
  • 6 Cheah CY, Campbell BA, Seymour JF. Primary breast lymphoma. Cancer Treat Rev 2014;40:900-8.
  • 7 Ryan G, Martinelli G, Kuper-Hommel M, Tsang R, Pruneri G, Yuen K, et al. Primary diffuse large B-cell lymphoma of the breast: Prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 2008;19:233-41.
  • 8 Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
  • 9 Jeanneret-Sozzi W, Taghian A, Epelbaum R, Poortmans P, Zwahlen D, Amsler B, et al. Primary breast lymphoma: Patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study. BMC Cancer 2008;8:86.
  • 10 Avilés A, Delgado S, Nambo MJ, Neri N, Murillo E, Cleto S. Primary breast lymphoma: Results of a controlled clinical trial. Oncology 2005;69:256-60.
  • 11 Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: The impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2010;21:1046-52.
  • 12 Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, et al. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: A single centre experience and review of the literature. Br J Haematol 2012;159:39-49.